JPRN-jRCTs041200079招募中2 期
Randomized phase II trial of neoadjuvant Gemcitabine/S-1 based chemoradiotherapy for potentially resectable pancreatic ductal adenocarcinoma - Randomized GSC-RPDAC trial
Mizuno Shugo0 个研究点目标入组 70 人开始时间: 2020年12月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 79age old（—）
- 性别
- All
入选标准
- •1. age at the time of registry is 20 or more, 79 or less
- •2. newly diagnosed invasive pancreatic ductal adenocarcinoma (PDAC) confirmed by imaging study and histological or cytological studies.
- •3. no distant metastasis
- •4. potentially resectable PDAC according to the resectability of Japan Pancreas Society 7th classification based on contrast enhanced multidetector CT imaging.
- •5. toleable curative resection
- •6. no previous anti-tumor treatment
- •7. Eastern Cooperative Oncology Group performance status, 0, 1
- •8. adequate hematological, hepatic, renal, and cardiopulmonary functions
- •9. adequate ability of oral intake
- •10. written informed consent before enrolling the study
排除标准
- •Patients who:
- •1) is allergic to the chemotherapeutic agents.
- •2) has pulmonary fibrosis or intestinal pneumonia.
- •3) has active infectious disease.
- •4) has simulatenous active cancer.
- •5) is plegnant or has possibility to become pregnant during the study.
- •6) is considered ineligible for enrolling the study by the principal investigator or sub-investigator.
研究者
相似试验
招募中
2 期
A phase II clinical trial of neoadjuvant gemcitabine and S-1 with concurrent radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinomaresectable and borderline resectable (BR-PV) pancreatic cancerJPRN-UMIN000053195Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University64
招募中
2 期
A phase II clinical trial of neoadjuvant gemcitabine and S-1 with concurrent hypofractionated radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinomaresectable and borderline resectable (BR-PV) pancreatic cancerJPRN-UMIN000038585Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University54
已完成
2 期
Randomized controlled phase II trial of gemcitabine/radiation combination therapy and gemcitabine monotherapy in locally advanced pancreatic cancer.locally advanced unresectable pancreatic cancerJPRN-UMIN000000624First Dept. Internal Medicine Gifu University Hospital60
已完成
2 期
Randomized controlled phase II trial of gemcitabine/radiation combination therapy and gemcitabine monotherapy in locally advanced biliary tract cancer.locally advanced unresectable biliary tract cancerJPRN-UMIN000000625First Dept. Internal Medicine Gifu University Hospital60
未知
2 期
Randomized phase II trial of gemcitabine(GEM) and carboplatin (CBDCA) with or without Dexamethasone(Dex) in untreated non-small cell lung cancer (NSCLC).on small cell lung cancerJPRN-UMIN000000547Kyoto Thoracic Oncology Research Group (KTORG)76